FAQ: What are predictive risk factors for disease severity in CD and UC?
GHAPPcast13 Feb 2025

FAQ: What are predictive risk factors for disease severity in CD and UC?

Thank you to Johnson & Johnson for your support of this FAQ Video Module.

In this FAQ video module, Erin Darguzas, NP, Gastroenterology Specialist at Northwestern Medicine, discusses the predictive risk factors for disease severity in Crohn’s disease and ulcerative colitis. Over the past 15 years, researchers have identified multiple prognostic factors that can help predict disease progression and guide individualized IBD management.

For moderate to severe Crohn’s disease, key factors include age at diagnosis (before 40), disease location (small bowel, colonic, or upper GI involvement), and disease behavior (structuring, penetrating, or perianal disease). Additional concerns include deep ulcers on endoscopy, significant weight loss, low albumin levels, smoking history, and genetic markers.

For ulcerative colitis, predictors of severity include age at diagnosis (before 50), frequency of disease flares, need for frequent therapy changes, and failure to achieve endoscopic remission. Pathology findings, such as persistent neutrophil infiltration, and treatment adherence history are also crucial in determining long-term outcomes.

Early identification of these prognostic factors allows for a more personalized treatment approach, improving patient outcomes in inflammatory bowel disease (IBD) management. Watch this video to learn more about Crohn’s disease and ulcerative colitis risk factors. For additional resources, visit the GHAPP website or download the GHAPP ACE app.

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(155)

FAQ: QUASAR Long Term Extension Interim Analysis

FAQ: QUASAR Long Term Extension Interim Analysis

Thank you to Johnson & Johnson for their support on this FAQ Video Module. In this educational video, Jamie Brogan, APRN, from Northwestern Medicine, reviews the latest QUASAR long-term extension data...

2 Juni 4min

Medication Review: Guselkumab IV vs SC Formulation

Medication Review: Guselkumab IV vs SC Formulation

Thank you to Johnson & Johnson for their support on this Medication Review Video Module. In this quick educational video, Angelina Collins, NP, from the University of California San Diego Inflammatory...

28 Maj 3min

FAQ: Recognizing OHE Risk in Patients with Chronic Liver Disease

FAQ: Recognizing OHE Risk in Patients with Chronic Liver Disease

Thank you to Salix for the support on this FAQ Video Module.This educational FAQ module, featuring Mikhail Alper, PA-C focuses on recognizing risk factors and early clinical indicators of Overt Hepati...

26 Maj 2min

FAQ: Phase 3 GALAXI 2 & 3: Extraintestinal Manifestations In Moderate to Severe Crohn’s Disease

FAQ: Phase 3 GALAXI 2 & 3: Extraintestinal Manifestations In Moderate to Severe Crohn’s Disease

Thank you to Johnson & Johnson for the support on this FAQ Video Module.This FAQ video features Janette Villalon, PA, who reviews the role of guselkumab in treating extraintestinal manifestations in p...

19 Maj 5min

Medication Review: Monotherapy vs. Combination Therapy: Relevance in IBD Treatment Strategy

Medication Review: Monotherapy vs. Combination Therapy: Relevance in IBD Treatment Strategy

Thank you to Celltrion for the support on this Medication Review Video Module.This medication review explores the evolving role of monotherapy versus combination therapy in the treatment of inflammato...

14 Maj 3min

Medication Review: Stable PK Supporting Continuous Inflammatory Control

Medication Review: Stable PK Supporting Continuous Inflammatory Control

Thank you to Celltrion for the support on this Medication Review Video Module.This medication review explores the role of stable pharmacokinetics (PK) in achieving continuous inflammatory control in i...

7 Maj 6min

Journal Club: ASTRO Phase 3 Study: Efficacy and Safety of SC Guselkumab

Journal Club: ASTRO Phase 3 Study: Efficacy and Safety of SC Guselkumab

Thank you to Johnson & Johnson for the support on this Journal Club Review Module.In this journal club video, Sharon Dudley Brown, CRNP, PhD, from the IBD Center at Johns Hopkins University, reviews t...

28 Apr 5min

Journal Club: Benefit–Risk Profile of Upadacitinib in Patient’s With Moderate to Severe UC and CD

Journal Club: Benefit–Risk Profile of Upadacitinib in Patient’s With Moderate to Severe UC and CD

Thank you to AbbVie for the support on this Journal Club Review Module.This journal club review episode explores the benefit–risk profile of Upadacitinib for patients with moderately to severely activ...

21 Apr 23min

Populärt inom Hälsa

somna-med-henrik
rss-bara-en-till-om-missbruk-medberoende-2
rss-vuxna-pa-latsas
inga-beiga-morsor
angestpodden
sexnoveller-deluxe
johannes-hansen-podcast
rss-viktmedicinpodden
rss-jossan-nina
sova-med-dan-horning
rss-the-house-podcast-3
rss-basta-livet
not-fanny-anymore
rss-relationsrevolutionen
sex-pa-riktigt-med-marika-smith
sa-in-i-sjalen
brottarbroder
rss-activation-podcast
rss-sjalsligt-avkladd
rss-fet-fakta-podcast